{"success":true,"data":{"pressRelease":{"id":"81298","rtpr_id":"nGNX8vG4py","ticker":"ALGS","exchange":"NASDAQ","all_tickers":["ALGS"],"title":"Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection","author":"Globe Newswire","published_at":"2026-07-06T20:05:00.552Z","article_body":"Breakthrough Therapy Designation granted for pevifoscorvir sodium in China\n\nSOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos\nTherapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company\nfocused on improving patient outcomes through best-in-class therapies for\nliver and viral diseases, today announced that it has received the upfront\npayment of $25M USD from the exclusive license deal of pevifoscorvir sodium in\nGreater China with Xiamen Amoytop Biotech Co., Ltd. (Amoytop). In addition,\npevifoscorvir sodium was granted Breakthrough Therapy Designation from the\nCenter for Drug Evaluation (CDE) of China’s National Medical Products\nAdministration (NMPA).\n\nUnder the terms of the agreement, Aligos is also eligible to receive up to\n$420M USD in clinical, regulatory, and sales milestones along with tiered,\nhigh single-digit royalties on net sales in Amoytop’s licensed territories.\nAligos retains all development and commercialization rights for pevifoscorvir\nsodium in the United States, Europe, South Korea, Japan, and all other\nmarkets.\n\n“We are pleased to provide this update on the collaboration with Amoytop,”\nstated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive\nOfficer of Aligos Therapeutics. “The joint steering committee has been\nformed, Breakthrough Therapy Designation has been granted for pevifoscorvir\nsodium in China, and we look forward to the continued progression of this\nprogram. In addition, we are continuing to build on our relationship with\nAmoytop’s planned entrance of our antisense oligonucleotide (ASO) ALG-170675\ninto the clinic in China in the third quarter of 2026. These two drug\ncandidates together demonstrate the promise of next-generation therapies that\nhave the potential to meaningfully change clinical outcomes for patients with\nchronic HBV infection.”\n\nBreakthrough Therapy Designation is granted to new drugs that treat serious\ndiseases with preliminary evidence of efficacy. Under this designation,\npevifoscorvir sodium is eligible for priority review of a New Drug Application\n(NDA) in China.\n\nAbout Aligos\n\nAligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology\ncompany founded with the mission to improve patient outcomes by developing\nbest-in-class therapies for the treatment of liver and viral diseases. Aligos\napplies its science driven approach and deep R&D expertise to advance its\npurpose-built pipeline of therapeutics for high unmet medical needs such as\nchronic hepatitis B virus infection, metabolic dysfunction-associated\nsteatohepatitis (MASH), obesity, and coronaviruses.\n\nFor more information, please visit www.aligos.com or follow us on LinkedIn or\nX.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe U.S. Private Securities Litigation Reform Act of 1995. Any statements in\nthis press release that are not historical facts may be considered\n“forward-looking statements,” including without limitation, statements\nregarding Aligos’ financial results and performance as well as research and\ndevelopment activities, including regulatory status and the timing of\nannouncements and updates relating to our regulatory filings and clinical\ntrials; statements about whether pevifoscorvir sodium development will\ncontinue to progress successfully in China or any jurisdiction, whether\nALG-170675 will enter clinical trials in the third quarter of 2026, and\nwhether pevifoscorvir sodium and ALG-170675 will change clinical outcomes for\npatients. Such forward looking statements are subject to substantial risks and\nuncertainties that could cause our development programs, future results,\nperformance, or achievements to differ materially from those anticipated in\nthe forward-looking statements. Such risks and uncertainties include, without\nlimitation, risks and uncertainties inherent in the drug development process,\nincluding Aligos’ clinical-stage of development, the process of designing\nand conducting clinical trials, the regulatory approval processes, reliance on\ncollaborators, and other matters that could affect the sufficiency of\nAligos’ capital resources to fund operations. For a further description of\nthe risks and uncertainties that could cause actual results to differ from\nthose anticipated in these forward-looking statements, as well as risks\nrelating to the business of Aligos in general, see Aligos’ Quarterly Report\non Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026\nand its future periodic reports to be filed or submitted with the Securities\nand Exchange Commission. Except as required by law, Aligos undertakes no\nobligation to update any forward-looking statements to reflect new\ninformation, events or circumstances, or to reflect the occurrence of\nunanticipated events.\n\nInvestor Contact\nAligos Therapeutics, Inc.\nJordyn Tarazi\nVice President, Investor Relations & Corporate Communications\n+1 (650) 910-0427\njtarazi@aligos.com\n\nMedia Contact\nInizio Evoke\nJake Robison\nVice President\nJake.Robison@inizioevoke.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/03ffbe89-c47f-4f83-b51f-f13a572e2cd1)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8vG4py","title":"Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection","author":"Globe Newswire","ticker":"ALGS","created":"2026-07-06T20:05:00.552Z","tickers":["ALGS"],"exchange":"NASDAQ","article_body":"Breakthrough Therapy Designation granted for pevifoscorvir sodium in China\n\nSOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos\nTherapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company\nfocused on improving patient outcomes through best-in-class therapies for\nliver and viral diseases, today announced that it has received the upfront\npayment of $25M USD from the exclusive license deal of pevifoscorvir sodium in\nGreater China with Xiamen Amoytop Biotech Co., Ltd. (Amoytop). In addition,\npevifoscorvir sodium was granted Breakthrough Therapy Designation from the\nCenter for Drug Evaluation (CDE) of China’s National Medical Products\nAdministration (NMPA).\n\nUnder the terms of the agreement, Aligos is also eligible to receive up to\n$420M USD in clinical, regulatory, and sales milestones along with tiered,\nhigh single-digit royalties on net sales in Amoytop’s licensed territories.\nAligos retains all development and commercialization rights for pevifoscorvir\nsodium in the United States, Europe, South Korea, Japan, and all other\nmarkets.\n\n“We are pleased to provide this update on the collaboration with Amoytop,”\nstated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive\nOfficer of Aligos Therapeutics. “The joint steering committee has been\nformed, Breakthrough Therapy Designation has been granted for pevifoscorvir\nsodium in China, and we look forward to the continued progression of this\nprogram. In addition, we are continuing to build on our relationship with\nAmoytop’s planned entrance of our antisense oligonucleotide (ASO) ALG-170675\ninto the clinic in China in the third quarter of 2026. These two drug\ncandidates together demonstrate the promise of next-generation therapies that\nhave the potential to meaningfully change clinical outcomes for patients with\nchronic HBV infection.”\n\nBreakthrough Therapy Designation is granted to new drugs that treat serious\ndiseases with preliminary evidence of efficacy. Under this designation,\npevifoscorvir sodium is eligible for priority review of a New Drug Application\n(NDA) in China.\n\nAbout Aligos\n\nAligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology\ncompany founded with the mission to improve patient outcomes by developing\nbest-in-class therapies for the treatment of liver and viral diseases. Aligos\napplies its science driven approach and deep R&D expertise to advance its\npurpose-built pipeline of therapeutics for high unmet medical needs such as\nchronic hepatitis B virus infection, metabolic dysfunction-associated\nsteatohepatitis (MASH), obesity, and coronaviruses.\n\nFor more information, please visit www.aligos.com or follow us on LinkedIn or\nX.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe U.S. Private Securities Litigation Reform Act of 1995. Any statements in\nthis press release that are not historical facts may be considered\n“forward-looking statements,” including without limitation, statements\nregarding Aligos’ financial results and performance as well as research and\ndevelopment activities, including regulatory status and the timing of\nannouncements and updates relating to our regulatory filings and clinical\ntrials; statements about whether pevifoscorvir sodium development will\ncontinue to progress successfully in China or any jurisdiction, whether\nALG-170675 will enter clinical trials in the third quarter of 2026, and\nwhether pevifoscorvir sodium and ALG-170675 will change clinical outcomes for\npatients. Such forward looking statements are subject to substantial risks and\nuncertainties that could cause our development programs, future results,\nperformance, or achievements to differ materially from those anticipated in\nthe forward-looking statements. Such risks and uncertainties include, without\nlimitation, risks and uncertainties inherent in the drug development process,\nincluding Aligos’ clinical-stage of development, the process of designing\nand conducting clinical trials, the regulatory approval processes, reliance on\ncollaborators, and other matters that could affect the sufficiency of\nAligos’ capital resources to fund operations. For a further description of\nthe risks and uncertainties that could cause actual results to differ from\nthose anticipated in these forward-looking statements, as well as risks\nrelating to the business of Aligos in general, see Aligos’ Quarterly Report\non Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026\nand its future periodic reports to be filed or submitted with the Securities\nand Exchange Commission. Except as required by law, Aligos undertakes no\nobligation to update any forward-looking statements to reflect new\ninformation, events or circumstances, or to reflect the occurrence of\nunanticipated events.\n\nInvestor Contact\nAligos Therapeutics, Inc.\nJordyn Tarazi\nVice President, Investor Relations & Corporate Communications\n+1 (650) 910-0427\njtarazi@aligos.com\n\nMedia Contact\nInizio Evoke\nJake Robison\nVice President\nJake.Robison@inizioevoke.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/03ffbe89-c47f-4f83-b51f-f13a572e2cd1)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-06T20:05:00.600680869Z","server_sent_at_ms":1783368300600},"received_at":"2026-07-06T20:05:00.666Z","source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322740/0/en/Aligos-Therapeutics-Receives-Upfront-Payment-of-25M-USD-from-the-Exclusive-License-Deal-of-Pevifoscorvir-Sodium-in-Greater-China-for-Chronic-Hepatitis-B-Virus-Infection.html"},"analysis":{"id":"70408","press_release_id":"81298","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Aligos Therapeutics received a $25 million upfront payment from partner Xiamen Amoytop Biotech following the exclusive license of pevifoscorvir sodium in Greater China for chronic hepatitis B.\n\nThe agreement includes up to $420 million in potential clinical and commercial milestones plus tiered royalties, while Aligos retains commercialization rights in the US, Europe, Japan, and South Korea.\n\nAdditionally, pevifoscorvir sodium was granted Breakthrough Therapy Designation by China's National Medical Products Administration, and the partners plan to advance ALG-170675 into the clinic in China during the third quarter of 2026.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Non-dilutive capital injection and China regulatory breakthrough validate the HBV program ahead of clinical entry for second asset."},"keyFigures":{"customDimensions":{"royalties":"tiered, high single-digit","upfront_payment_usd":25000000,"potential_milestones_usd":420000000}},"quotedText":"These two drug candidates together demonstrate the promise of next-generation therapies that have the potential to meaningfully change clinical outcomes for patients with chronic HBV infection.","namedEntities":{"people":[{"name":"Lawrence Blatt","role":"Chairman, President, and Chief Executive Officer"},{"name":"Jordyn Tarazi","role":"Vice President, Investor Relations & Corporate Communications"},{"name":"Jake Robison","role":"Vice President"}],"products":["pevifoscorvir sodium","ALG-170675"],"companies":[{"name":"Aligos Therapeutics, Inc.","ticker":"ALGS"},{"name":"Xiamen Amoytop Biotech Co., Ltd.","relationship":"partner"},{"name":"Inizio Evoke","relationship":"Media Contact"}],"dollarAmounts":[{"amount":"$25M USD","context":"upfront payment from exclusive license deal"},{"amount":"$420M USD","context":"potential clinical, regulatory, and sales milestones"}]},"materialImpact":{"score":4,"reasoning":"Receipt of $25M upfront payment provides immediate non-dilutive funding, while the Breakthrough Therapy Designation in China significantly de-risks the asset's regulatory path in a key market. The deal structure includes up to $420M in future milestones."},"tickerRelevance":{"others":[],"primary":"ALGS"},"globalImportance":35,"audienceRelevance":30,"eventTypeSecondary":["regulatory"],"importanceComponents":{"cashInflow":"$25M_upfront_non_dilutive","tickerTier":"small_cap_biotech","eventGravity":"partnership_deal_and_regulatory_milestone","sectorWeight":"biotech_regulatory_news"}},"event_type":"partnership","event_type_secondary":["regulatory"],"sentiment":"bullish","material_impact_score":4,"narrative":"Aligos Therapeutics received a $25 million upfront payment from partner Xiamen Amoytop Biotech following the exclusive license of pevifoscorvir sodium in Greater China for chronic hepatitis B.\n\nThe agreement includes up to $420 million in potential clinical and commercial milestones plus tiered royalties, while Aligos retains commercialization rights in the US, Europe, Japan, and South Korea.\n\nAdditionally, pevifoscorvir sodium was granted Breakthrough Therapy Designation by China's National Medical Products Administration, and the partners plan to advance ALG-170675 into the clinic in China during the third quarter of 2026.","key_figures":{"customDimensions":{"royalties":"tiered, high single-digit","upfront_payment_usd":25000000,"potential_milestones_usd":420000000}},"named_entities":{"people":[{"name":"Lawrence Blatt","role":"Chairman, President, and Chief Executive Officer"},{"name":"Jordyn Tarazi","role":"Vice President, Investor Relations & Corporate Communications"},{"name":"Jake Robison","role":"Vice President"}],"products":["pevifoscorvir sodium","ALG-170675"],"companies":[{"name":"Aligos Therapeutics, Inc.","ticker":"ALGS"},{"name":"Xiamen Amoytop Biotech Co., Ltd.","relationship":"partner"},{"name":"Inizio Evoke","relationship":"Media Contact"}],"dollarAmounts":[{"amount":"$25M USD","context":"upfront payment from exclusive license deal"},{"amount":"$420M USD","context":"potential clinical, regulatory, and sales milestones"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-06T20:17:55.639Z","global_importance":35,"audience_relevance":30,"importance_components":{"cashInflow":"$25M_upfront_non_dilutive","tickerTier":"small_cap_biotech","eventGravity":"partnership_deal_and_regulatory_milestone","sectorWeight":"biotech_regulatory_news"}},"durationMs":null,"modelName":"george-droid-qwen-72b"}}